|
Seroquel XR Formulation Patent Deemed Valid, Good Through 2017
With the initial version of AstraZeneca’s antipsychotic Seroquel now victim to a host of generic rivals, the drugmaker can be confident the product’s extended-release version is likely safe for another five years.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapCourt Stays Seven Wyeth, Teva Pay-for-Delay Cases Pending Supreme Court Petitions PhRMA Asks Supreme Court to Reverse Third Circuit’s ‘Rogue’ Anti-Pay-for-Delay DecisionDistrict Court Stays Four Cephalon Pay-for-Delay Cases Pending Merck’s Supreme Court Petition
|
Subscribe
Archives